Extrachromosomal DNA-Driven Oncogene Spatial Heterogeneity and Evolution in Glioblastoma
- PMID: 40920091
- DOI: 10.1158/2159-8290.CD-24-1555
Extrachromosomal DNA-Driven Oncogene Spatial Heterogeneity and Evolution in Glioblastoma
Abstract
Oncogenes amplified on extrachromosomal DNA (ecDNA) contribute to treatment resistance and poor survival across cancers. Currently, the spatiotemporal evolution of ecDNA remains poorly understood. In this study, we integrate computational modeling with samples from 94 treatment-naive human glioblastomas (GBM) to investigate the spatiotemporal evolution of ecDNA. We observe oncogene-specific patterns of ecDNA spatial heterogeneity, emerging from random ecDNA segregation and differing fitness advantages. Unlike PDGFRA-ecDNAs, EGFR-ecDNAs often accumulate prior to clonal expansions, conferring strong fitness advantages and reaching high abundances. In corroboration, we observe pretumor ecDNA accumulation in vivo in genetically engineered mouse neural stem cells. Variant and wild-type EGFR-ecDNAs often coexist in GBM. Those variant EGFR-ecDNAs, most commonly EGFRvIII-ecDNA, always derive from preexisting wild-type EGFR-ecDNAs, occur early, and reach high abundance. Our results suggest that the ecDNA oncogenic makeup determines unique evolutionary trajectories. New concepts such as ecDNA clonality and heteroplasmy require a refined evolutionary interpretation of genomic data in a large subset of GBMs.
Significance: We study spatial patterns of ecDNA-amplified oncogenes and their evolutionary properties in human GBM, revealing an ecDNA landscape and ecDNA oncogene-specific evolutionary histories. ecDNA accumulation can precede clonal expansion, facilitating the emergence of EGFR oncogenic variants, reframing our interpretation of genomic data in a large subset of GBMs. See related article by Korsah et al., p. XX.
©2025 The Authors; Published by the American Association for Cancer Research.
Update of
-
Extrachromosomal DNA driven oncogene spatial heterogeneity and evolution in glioblastoma.bioRxiv [Preprint]. 2024 Oct 25:2024.10.22.619657. doi: 10.1101/2024.10.22.619657. bioRxiv. 2024. Update in: Cancer Discov. 2025 Sep 08:OF1-OF18. doi: 10.1158/2159-8290.CD-24-1555. PMID: 39484416 Free PMC article. Updated. Preprint.
Grants and funding
- R01 CA282913/CA/NCI NIH HHS/United States
- CGCATF-2021/100012/Cancer Research UK (CRUK)
- CGCATF-2021/100025/Cancer Research UK (CRUK)
- OT2CA278688/National Cancer Institute (NCI)
- OT2CA278635/National Cancer Institute (NCI)
- R01-GM114362/National Cancer Institute (NCI)
- MGU045/Barts Charity
- MR/V02342X/1/UK Research and Innovation (UKRI)
- 835297/HORIZON EUROPE European Research Council (ERC)
- FC001169/WT_/Wellcome Trust/United Kingdom
- FC001169/WT_/Wellcome Trust/United Kingdom
- FC001169/WT_/Wellcome Trust/United Kingdom
- NIH K00CA274692/National Cancer Institute (NCI)
- C11496/A17786/Cancer Research UK (CRUK)
- C416/A21999/Cancer Research UK (CRUK)
- C11496/A30025/Cancer Research UK (CRUK)
- ID16584/Novo Nordisk Foundation Center for Basic Metabolic Research (NovoNordisk Foundation Center for Basic Metabolic Research)
- RP/EA/180007/Royal Society (The Royal Society)
- 21-029-ASP/Mark Foundation For Cancer Research (The Mark Foundation for Cancer Research)
- U24-CA264379/National Cancer Institute (NCI)
- NIH K99CA286968/National Cancer Institute (NCI)
- P30 CA008748/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous